88073859 - AB CHECK

Information

  • Trademark
  • 88073859
  • Serial Number
    88073859
  • Registration Number
    7133412
  • Filing Date
    August 10, 2018
    6 years ago
  • Registration Date
    August 08, 2023
    a year ago
  • Transaction Date
    August 08, 2023
    a year ago
  • Status Date
    August 08, 2023
    a year ago
  • Published for Opposition Date
    September 29, 2020
    4 years ago
  • Location Date
    July 05, 2023
    a year ago
  • First Use Anywhere Date
    September 27, 2021
    3 years ago
  • First Use In Commerce Date
    September 27, 2021
    3 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    AVENT, TEAGUE A
  • Attorney Docket Number
    50125-T89001
    Attorney Name
    Karen L. Elbing
    Law Office Assigned Location Code
    N70
  • Owners
Mark Drawing Code
3000
Mark Identification
AB CHECK
Case File Statements
  • DM0000: The mark consists of letters "AB" and "CHECK" separated by an array of circles.
  • CC0000: Color is not claimed as a feature of the mark.
  • D10000: "AB" OR "CHECK"
  • GS0421: Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, medical research in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely, medical research in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, medical research in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely, in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely, scientific research in the field of antibody research and antibody optimization
Case File Event Statements
  • 8/8/2023 - a year ago
    55 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 8/8/2023 - a year ago
    54 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 7/6/2023 - a year ago
    53 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Type: SUNA
  • 7/5/2023 - a year ago
    52 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Type: CNPR
  • 6/9/2023 - a year ago
    51 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 6/8/2023 - a year ago
    50 - STATEMENT OF USE PROCESSING COMPLETE Type: SUPC
  • 6/8/2023 - a year ago
    49 - SOU EXTENSION 5 GRANTED Type: EX5G
  • 5/24/2023 - a year ago
    48 - SOU EXTENSION 5 FILED Type: EXT5
  • 5/24/2023 - a year ago
    47 - USE AMENDMENT FILED Type: IUAF
  • 5/30/2023 - a year ago
    46 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 5/24/2023 - a year ago
    45 - TEAS EXTENSION RECEIVED Type: EEXT
  • 5/24/2023 - a year ago
    44 - TEAS STATEMENT OF USE RECEIVED Type: EISU
  • 11/1/2022 - 2 years ago
    43 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 10/28/2022 - 2 years ago
    42 - SOU EXTENSION 4 GRANTED Type: EX4G
  • 10/28/2022 - 2 years ago
    41 - SOU EXTENSION 4 FILED Type: EXT4
  • 10/28/2022 - 2 years ago
    40 - TEAS EXTENSION RECEIVED Type: EEXT
  • 5/19/2022 - 2 years ago
    39 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 5/17/2022 - 2 years ago
    38 - SOU EXTENSION 3 GRANTED Type: EX3G
  • 5/17/2022 - 2 years ago
    37 - SOU EXTENSION 3 FILED Type: EXT3
  • 5/17/2022 - 2 years ago
    36 - TEAS EXTENSION RECEIVED Type: EEXT
  • 10/28/2021 - 3 years ago
    35 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 10/26/2021 - 3 years ago
    34 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 10/26/2021 - 3 years ago
    33 - SOU EXTENSION 2 FILED Type: EXT2
  • 10/26/2021 - 3 years ago
    32 - TEAS EXTENSION RECEIVED Type: EEXT
  • 4/22/2021 - 3 years ago
    31 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 4/20/2021 - 3 years ago
    30 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 4/20/2021 - 3 years ago
    29 - SOU EXTENSION 1 FILED Type: EXT1
  • 4/20/2021 - 3 years ago
    28 - TEAS EXTENSION RECEIVED Type: EEXT
  • 11/24/2020 - 4 years ago
    27 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/29/2020 - 4 years ago
    26 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/29/2020 - 4 years ago
    25 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 9/9/2020 - 4 years ago
    24 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 8/26/2020 - 4 years ago
    23 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 6/25/2020 - 4 years ago
    22 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 6/25/2020 - 4 years ago
    21 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 6/25/2020 - 4 years ago
    20 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 4/19/2020 - 4 years ago
    19 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 4/19/2020 - 4 years ago
    18 - FINAL REFUSAL E-MAILED Type: GNFR
  • 4/19/2020 - 4 years ago
    17 - FINAL REFUSAL WRITTEN Type: CNFR
  • 1/16/2020 - 4 years ago
    16 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/15/2020 - 4 years ago
    15 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/15/2020 - 4 years ago
    14 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/17/2019 - 5 years ago
    13 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 7/17/2019 - 5 years ago
    12 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 7/17/2019 - 5 years ago
    11 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/13/2019 - 5 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 6/13/2019 - 5 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 6/13/2019 - 5 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/2/2019 - 6 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/2/2019 - 6 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 1/2/2019 - 6 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/28/2018 - 6 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/21/2018 - 6 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 8/18/2018 - 6 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 8/14/2018 - 6 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP